Definitive Healthcare Launches Passport Analytics Suite

Definitive Healthcare (Nasdaq: DH), an industry leader in healthcare commercial intelligence, today announced the general availability of the Passport Analytics Suite, a set of products that helps life science organizations develop, launch, and commercialize products more efficiently by delivering data-agnostic analytics on-demand.

The Passport Analytics Suite is powered by Analytical Wizards, the company acquired by Definitive Healthcare in February 2022.

“We are excited to launch this suite of highly configurable and scalable analytics products built on top of the fabulous technology that we acquired with Analytical Wizards,” said Jason Krantz, founder and CEO of Definitive Healthcare. “With these tools, clients can effectively assess and optimize brand performance and dial in the optimal promotional mix. The Passport Analytics Suite helps clients optimize the entire commercialization process, from early-stage business planning needs through post-launch performance acceleration.”

Addressing critical pre-and post-commercial needs for life sciences

Comprised of two products – Passport Promotional Analytics and Passport Planning & Performance – the Passport Analytics Suite delivers commercial intelligence around product planning, product performance and marketing optimization. The suite combines a highly configurable front-end application environment with an automated, efficient and scalable back-end cloud platform. Clients can quickly and seamlessly combine data from virtually any internal or third-party source and then use patent-pending analytics to immediately obtain the intelligence needed to reach peak revenue and profit.

“Sanofi has mission-critical data about sales and marketing spread across our global organization,” said Peter Ingraham, Head of the Global Analytics Center of Excellence at Sanofi. “With the state-of-the-art technology from Analytical Wizards, we can quickly bring it all together in one place and run analytics at-scale that enable us to dynamically adjust our global marketing spend at a country level across our brand portfolio and identify strategic opportunities.”

The Passport Analytics Suite enables life sciences organizations to establish an analytics on-demand environment at-scale. The suite can integrate internal sales and marketing data with third-party big data on claims, EMR and lab/diagnostics data, as well as publicly available datasets including CMS, clinicaltrials.gov, and CDC epidemiology. The suite can also integrate data from Definitive Healthcare’s proprietary platform, including the Definitive ID and its industry-leading provider reference and affiliation data.  However, Definitive Healthcare data is not required for a successful implementation of the Passport Analytics Suite.

With the Passport Analytics Suite, life sciences organizations can inform product development with high-quality intelligence by cleansing and combining data from multiple sources. Users can easily aggregate unstructured data from the specific sources that matter to them, saving time and resources. The Passport Analytics Suite is designed to work with data from any cloud or IT infrastructure, unlike competitive solutions which base reporting on limited or proprietary data inputs.

“The Passport Analytics Suite is unique in its ability to combine AI-driven data science methodologies with deep expertise in the life sciences,” said Ram Sharma, founder and CEO of Analytical Wizards. “The Passport Analytics Suite delivers configurable analytics on-demand, allowing clients to cut and re-cut data as they want in a secure, self-service environment. The easy-to-use products enable team members from across an organization to create value by reporting on a single source of truth, and then looking at it from multiple angles.”

Optimizing brand performance, promotional investment and omnichannel execution

The first release of the Passport Analytics Suite is built on top of two existing products from Analytical Wizards and further extends their value:

  • Passport Planning & Performance, built on top of the Ize product from Analytical Wizards, optimizes the pathway to FDA approval and subsequent commercialization by improving market opportunity selection, accelerating clinical trials and informing business decisions. Passport Planning & Performance includes four distinct, user-friendly modules (Opportunity Assessment, 360 KPI Scorecard, Clinical Trial Accelerator, and Dynamic Targeting) which enable clients to size potential markets, measure performance with interactive KPI dashboards, identify the fastest recruiting investigators and predict patients eligible to receive treatment.
  • Passport Promotional Analytics, built on top of the Wiz product from Analytical Wizards, helps life science organizations attain peak revenue and profit by improving customer segmentation, maximizing impact of promotional tactics and effectively allocating omnichannel budget. Passport Promotional Analytics includes four distinct, user-friendly modules (Promotion Mix, Channel Insight, Customer Segmentation, and Campaign Performance) which enable clients to understand the preferences of prospect segments, target high-value healthcare providers and identify the most engaging marketing tactics and channels.

“As a long-time user of the Wiz product from Analytical Wizards, we’ve seen significant improvement in our go-to-market strategy by using their world-class analytics,” said Greg Nagle, SVP and Head of Commercial Analytics at Sumitovant Biopharma. “I look forward to the new types of healthcare commercial intelligence that Analytical Wizards and Definitive Healthcare will create together.”

For more information about the Passport Analytics Suite, visit https://www.definitivehc.com/passport.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”